YCBD · cbdMD, Inc.
$0.44
+0.01 (+2.44%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s ability to continue as a going concern is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that these financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.22M
Shares
11.21M
Volume · Oct 5
81.43K
Avg daily vol (3M)
436.46K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.43
Open$0.46
Day$0.43–0.46
52W close$0.43–2.27
Avg vol 30d685K
Short int511K · 4.6% float · 1.9d
Short vol20%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Jan 14, 2027
Est · unconfirmed
· in 14 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-61.4%
Trailing year
Short interest
4.6%
Latest settlement · 1.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−14%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−41%
trailing
YTD return
−68%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.56% of float · ▼ -2.2% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−1%
Y/Y
Gross margin
62%
expanding
EPS growth
+92%
Y/Y
Free cash flow
$-1.6M
Quant / Vol
risk profile
Volatility
152%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 13, 2026
Monthly OPEX savings from cost reduction program
· fourth fiscal quarter
$100,000 – $150,000
Prior guidance
period ended
· from the 8-K filed Nov 25, 2025
Net sales revenue
· fiscal 2025
$19.1M – $19.3M
Net sales revenue
· fourth quarter of fiscal 2025
$4.7M – $4.9M
Guided vs delivered
· last 1 settled
Net sales
first quarter of our fiscal 2022 ending December 31, 2021
guided $14.9M – $15.5M
$9.32M
Miss −38.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.56% of float · ▼ -2.2% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $2
vs 200-day avg -43%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
YCBD
this stock
cbdMD, Inc.
|
$5.22M | -68.2% | -1.5% | — | 4.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +27.1% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.8% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| YCBD | -7.3% | -9.7% | -41.0% | -5.2% | -68.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -8.5% | -10.3% | -52.6% | -6.8% | -81.8% |